The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.a

Left or biventricular dysfunction/failure

Publications

Hayek ER, Speakman E, Rehmus E

Acute doxorubicin cardiotoxicity.

The New England journal of medicine. 2005;352(23):2456-7

Singal PK, Iliskovic N

Doxorubicin-induced cardiomyopathy.

The New England journal of medicine. 1998;339(13):900-5

Bristow MR, Mason JW, Billingham ME, Daniels JR

Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization.

Annals of internal medicine. 1978;88(2):168-75

Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM

Risk factors for doxorubicin-induced congestive heart failure.

Annals of internal medicine. 1979;91(5):710-7